Chronic granulocytic leukemia: Recent information on pathogenesis, diagnosis, and disease monitoring

Mayo Clinic Proceedings

Volumn 72, Issue 5, 1997, Pages 445-452

  Tefferi, Ayalew ^a   Litzow, Mark R ^b   Noel, Pierre ^c   Dewald, Gordon W ^b  

^a Division of Hematology and Internal Medicine   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 22Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 9; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; PHILADELPHIA 1 CHROMOSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030947692     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.5.445     Document Type: Article

References (76)

1. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987; 49:127-167
2. Fauser AA, Kanz L, Bross KJ, Lohr GW. T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 1985; 75:1080-1082
3. Tefferi A, Schad CR, Pruthi RK, Ahmann GJ, Spurbeck JL, Dewald GW. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genet Cytogenet 1995; 83:61-64
4. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82:691-703
5. van der Plas DC, Grosveld G, Hagemeijer A. Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML. Cancer Genet Cytogenet 1991; 52:143-156
6. Hicks GA, Dewald GW. Incidence and types of variant Ph chromosomes in 378 patients with a Ph chromosome [abstract]. Karyogram 1985; 11:105
7. Martiat P, Michaux JL, Rodhain J (Groupe Français de Cytogenetique Hematologique). Philadelphia-negative (Plr) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. Blood 1991; 78:205-211
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia; proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87:746-754
9. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science 1960; 132:1497
10. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973; 243:290-293
11. Heisterkamp AN, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306:239-242
12. Groffen J, Heisterkamp N, Stephenson JR, van Kessel AG, de Klein A, Grosveld G, et al. c-sis is translocated from chromosome 22 to chromosome 9 in chronic myelocytic leukemia. J Exp Med 1983; 158:9-15
13. Bernards A, Rubin CM, Westbrook CA, Paskind M, Baltimore D. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol 1987; 7:3231-3236
14. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-99
15. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985; 315:758-761
16. Matsue K, Miyamoto T, Ito M, Tsukuda K. Late appearance of the Philadelphia chromosome with monosomy 7 in a patient with de novo AML with trilineage myelodysplasia. Am J Hematol 1995; 49:341-346
17. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986; 67:415-420
18. Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987;70:948-953
19. Rodenhuis S, Smets LA, Slater RM, Behrendt H, Veerman AJ. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia [letter]. N Engl J Med 1985; 313:51-52
20. Erikson J, Griffin CA, ar-Rushdi A, Valtieri M, Hoxie J, Finan J, et al. Heterogeneity of chromosome 22 breakpoint in Philadelphiapositive (Ph+) acute lymphocytic leukemia. Proc Natl Acad Sci USA 1986; 83:1807-1811
21. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37:1035-1042
22. Seeker-Walker LM, Cooke HM, Browett PJ, Shippey CA, Norton JD, Coustan-Smith E, et al. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia. Blood 1988; 72:784-791
23. Tefferi A, Bren GD, Wagner KV, Schaid DJ, Ash RC, Thibodeau SN. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia 1990; 4:839-842
24. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. Leukemia 1995; 9:1648-1652
25. Dewald GW, Schad CR, Christensen ER, Tiède AL, Zinsmeister AR, Spurbeck JL, et al. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet Cytogenet 1993; 71:7-14
26. Wiedemann LM, Karhi KK, Shivji MK, Rayter SI, Pegram SM, Dowden G, et al. The correlation of breakpoint cluster region rearrangement and p2\0phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988; 71:349-355
27. Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64:1246-1254
28. Selleri L, Narni F, Emilia G, Colo A, Zucchini P, Venturelli D, et al. Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region. Blood 1987; 70:1659-1664
29. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996; 88:2236-2240
30. Gale RP, Canaani E. An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA 1984; 81:5648-5652
31. Canaani E, Gale RP, Steiner-Saltz D, Berrebi A, Aghai E, Januszewicz E. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet 1984; 1:593-595
32. Stam K, Heisterkamp N, Reynolds FH Jr, Groffen J. Evidence that the phi gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol 1987; 7:1955-1960
33. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P2\0bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-830
34. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990; 87:66496653
35. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple haemapoietic neoplasms in mice. EMBOJ 1990; 9:1069-1078
36. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S, et al. A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 1989; 9:2798-2805
37. Honda H, Fujii T, Takatoku M, Mano H, Witte ON, Yazaki Y, et al. Expression of p2\0bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 1995; 85:2853-2861
38. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcrlabl transgenic mice. Nature 1990; 344:251-253
39. Clark SS, Chen E, Fizzotti M, Witte ON, Malkovska V. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. J Virol 1993; 67:60336046
40. Voncken JW, Griffiths S, Greaves MF, Pattengale PK, Heisterkamp N, Groffen J. Restricted oncogenicity of BCR/ABL p 190 in transgenic mice. Cancer Res 1992; 52:4534-4539
41. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol Cell Biol 1991; 11:4710-4716
42. Franz WM, Berger P, Wang JY. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBOJ 1989; 8:137-147
43. Caracciolo D, Valtieri M, Venturelli D, Peschle C, Gewirtz AM, Calabretta B. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science 1989; 245:1107-1110
44. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosomepositive human leukemias. Mol Cell Biol 1991; 11:1785-1792
45. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991 ; 66:161 -171
46. McWhirter JR, Wang JY. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by her sequences in bcrlabl fusion proteins. Mol Cell Biol 1991; 11:1553-1565
47. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75:175-185
48. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia leukemia. Blood 1994; 84:1731-1736
49. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, et al. The proto-oncogene product p!20CBL and the adaptor proteins CRKL and C-CRK link c-ABL, p!90BCR/ABL and P210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene 1996; 12:839-846
50. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis of BCR-ABL in chronic myeloid leukemia. Blood 1994; 83:2038-2044
51. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 1995; 92:5287-5291
52. Daley GQ, McLaughlin J, Witte ON, Baltimore D. The CML-specific P210 bcrlabl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 1987; 237:532-535
53. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995; 270:29145-29150
54. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992; 90:1232-1241
55. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, et al. C7?-AL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148-1158
56. Sugahara H, Kanakura Y, Furitsu T, Ishihara K, Oritani K, Ikeda H, et al. Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5. J ExpMed 1994; 179:1757-1766
57. Hagemeijer A, Bartram CR, Smit EM, van Agthoven AJ, Bootsma D. Is the chromosomal region 9q34 always involved in variants of the Phi translocation? Cancer Genet Cytogenet 1984; 13:1-16
58. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. LeukLymphoma 1993; ll(Suppl 1):11-15
59. Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72:294-298
60. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-825
61. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114:532-538
62. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. BrJHaematol 1993; 83:399-403
63. Allan NC, Richards SM, Shepherd PC (UK Médical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia). UK Medical Research Council randomised, multicentre trial of interferon-anl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345:1392-1397
64. Nolle M, Werner M, Ewig M, von Wasielewski R, Wilkens L, Link H, et al. Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. Leuk Lymphoma 1996; 22:287-294
65. Amiel A, Yarkoni S, Fejgin M, Gaber E, Nagler A, Manor Y, et al. Clinical detection of BCR-aW fusion by in situ hybridization in chronic myelogenous leukemia. Cancer Genet Cytogenet 1993; 65:32-34
66. Amiel A, Yarkoni S, Slavin S, Or R, Lorberboum-Galski H, Fejgin M, et al. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization. Cancer Genet Cytogenet 1994; 76:59-64
67. Cox-Froncillo MC, Cantonetti M, Masi M, Lentini R, Giudiceandrea P, Maffei L, et al. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. Cancer Genet Cytogenet 1995; 84:15-18
68. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995; 86:2343-2349
69. Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, et al. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. JClinOncol 1997; 15:26-36
70. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Pherwani R, Rios MB, Stass SA, et al. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 1995; 85:2705-2710
71. Delfau MH, Kerckaert JP, Collyn d'Hooghe M, Pénaux P, Lai JL, Jouet JP, et al. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukemia 1990; 4:1-5
72. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86:3118-3122
73. Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84:67-74
74. Radien JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85:2632-2638
75. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82:1929-1936
76. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87:1549-1555